In support, glucosamine was able to reduce colitis-associated symptoms in DSS-treated mice by reducing TNF-α, IL-1β, and NF-kB expression in the colonic mucosa, and increasing the expression of ZO-1 and occludin tight junction proteins [12]. This evidence concerns the gene NFKB1 and colitis.